ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana.
 PMID: 17827059       2007       Journal of clinical virology
Abstract: The L10I, L10V, V11I and E35G minor mutations were seen in four patients, while the V179E was observed in a patient with subtype G.


  HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
 PMID: 17500586       2007       PLoS computational biology
Method: PI-selected mutations included L10I/V/F/R, V11I, K20R/M/I/T, L23I, L24I, D30N, V32I, L33F/I, E34Q, E35G, M36I/V, K43T, M46I/L/V, G48V/M, I50V/L, F53L, I54V/M/L/T/A/S, K55R, Q58E, L63P,


  A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
 PMID: 17227139       2007       PLoS medicine
Method: In addition, the model was also adjusted on use of nelfinavir at baseline and on the number of PI mutations (L10IRVF, K20RM, M36I, A71VT, G73SA, V82AFTS, L90M) found to be associated with the virological response in univariate analyses in this subset of patients.


  Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
 PMID: 17425479       2007       Expert opinion on pharmacotherapy
Abstract: The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V.


  Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
 PMID: 16856615       2006       Antiviral therapy
Abstract: The Reyaphar score included 12 baseline protease substitutions from the International AIDS Society USA list that were associated with poorer VR: L10I/F/R/V, K20I/M/R, L241, M461/L, 154L/M/T/V, L63P, A71I/L/V/T, G73A/C/F/T, V771, V82A/F/S/T, 184V, L90M and the polymorphism substitution Q58E.


  Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures.
 PMID: 16553322       2005       Revista do Instituto de Medicina Tropical de Sao Paulo
Abstract: The most frequent mutations were M41L, M184V, and T215FY in RT and L62PI, L10FIRV and M36I in PT.


  Tipranavir: a ritonavir-boosted protease inhibitor.
 PMID: 16060700       2005       Drugs
Abstract: Analysis of clinical isolates from treatment-experienced patients identified the following tipranavir resistance-associated HIV protease mutations: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V.


  [Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile].
 PMID: 15880183       2005       Revista medica de Chile
Abstract: Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R.


  Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
 PMID: 15748098       2005       Drugs
Abstract: When used with ritonavir, the accumulation of six or more mutations among L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S and I84V leads to clear decrease in viral response to treatment.


  Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.
 PMID: 19825125       2005       Journal of the International AIDS Society
Table: L10V



Browser Board

 Co-occurred Entities




   Filtrator